NEW YORK (GenomeWeb News) – Monogram Biosciences reported after the close of the market on Wednesday that its first-quarter revenues fell 4 percent on lower product revenue and its net loss surged on a convertible debt valuation adjustment.

The South San Francisco, Calif.-based pharmacogenomics test maker brought in total revenues of $14.2 million for the three-month period ended March 31, compared to revenues of $14.8 million for the first quarter of 2008. Its product revenue fell to $13.6 million from $14 million, and its contract revenue slipped to $605,000 from $820,000.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.